Enlivex Therapeutics Ltd.

3.57-0.0900-2.46%Vol 28.02K1Y Perf -31.46%
Mar 24th, 2023 15:08 DELAYED
BID3.53 ASK3.57
Open3.75 Previous Close3.66
Pre-Market- After-Market-
 - -  - -%
Target Price
15.00 
Analyst Rating
Strong Buy 1.00
Potential %
320.17 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
2.87 
Earnings Rating
Market Cap48.06M 
Earnings Date
5th May 2023
Alpha0.00 Standard Deviation0.28
Beta1.12 

Today's Price Range

3.533.78

52W Range

3.428.64

5 Year PE Ratio Range

-4.10-1.10

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.28%
1 Month
-7.03%
3 Months
-8.23%
6 Months
-13.14%
1 Year
-31.46%
3 Years
-18.49%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ENLV3.57-0.0900-2.46
AAPL160.251.32000.83
GOOG106.08-0.1850-0.17
MSFT280.572.91001.05
XOM103.530.12000.12
WFC36.23-0.3800-1.04
JNJ152.651.52001.01
FB196.640.99000.51
GE91.37-0.2200-0.24
JPM124.91-1.9300-1.52
 
Earnings HistoryEstimateReportedSurprise %
Q03 2022-0.29-0.31-6.90
Q02 2022-0.45-0.54-20.00
Q01 2022-0.41-0.45-9.76
Q04 2021--0.26-
Q03 2021-0.21-0.199.52
Q02 2021-0.26-0.1734.62
Q01 2021-0.21-0.199.52
Q04 2020--0.43-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date5th May 2023
Estimated EPS Next Report-0.38
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume28.02K
Shares Outstanding13.46K
Shares Float17.22M
Trades Count141
Dollar Volume101.91K
Avg. Volume19.21K
Avg. Weekly Volume12.97K
Avg. Monthly Volume16.96K
Avg. Quarterly Volume27.70K

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) stock closed at 3.57 per share at the end of the most recent trading day (a -2.46% change compared to the prior day closing price) with a volume of 28.02K shares and market capitalization of 48.06M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. Enlivex Therapeutics Ltd. CEO is Oren Hershkovitz.

The one-year performance of Enlivex Therapeutics Ltd. stock is -31.46%, while year-to-date (YTD) performance is -9.33%. ENLV stock has a five-year performance of %. Its 52-week range is between 3.42 and 8.64, which gives ENLV stock a 52-week price range ratio of 2.87%

Enlivex Therapeutics Ltd. currently has a PE ratio of -2.70, a price-to-book (PB) ratio of 1.24, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -36.78%, a ROC of -35.35% and a ROE of -41.49%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Enlivex Therapeutics Ltd., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.38 for the next earnings report. Enlivex Therapeutics Ltd.’s next earnings report date is 05th May 2023.

The consensus rating of Wall Street analysts for Enlivex Therapeutics Ltd. is Strong Buy (1), with a target price of $15, which is +320.17% compared to the current price. The earnings rating for Enlivex Therapeutics Ltd. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Enlivex Therapeutics Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Enlivex Therapeutics Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 18.23, ATR14 : 0.15, CCI20 : -53.29, Chaikin Money Flow : -0.16, MACD : -0.13, Money Flow Index : 27.90, ROC : -6.79, RSI : 34.53, STOCH (14,3) : 26.32, STOCH RSI : 0.56, UO : 42.06, Williams %R : -73.68), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Enlivex Therapeutics Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

CEO: Oren Hershkovitz

Telephone: +972 26208072

Address: 14 Einstein Street, Nes Ziona 7403618, , IL

Number of employees: 36

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

59%41%

Bearish Bullish

56%44%


News

Stocktwits